They also showed that DETANONOate (a nitric oxide donor) treatment reduces NF-κB DNA binding activity and Snail pathway inhibition, which mediates anti-metastatic properties in prostate cancer patients [105]. This evidence concerns the gene SNAI1 and prostate carcinoma.